Cogenics
About Cogenics
Gene synthesis, sequencing, and molecular biology services are offered by Cogenics in the biotechnology sector. Next-generation sequencing, Sanger sequencing, PCR, and related techniques are encompassed within these offerings. Plasmid preparation, oligo synthesis, and nucleic acid extraction are included among the core services. Preclinical and clinical support is provided through GLP-compliant testing and CLIA-certified variant confirmation. Research in gene therapy, cancer, and infectious diseases is facilitated by these capabilities.
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Beckman Coulter
(Apr 01, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cogenics
Detailed funding history for Cogenics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cogenics
Cogenics has secured backing from 1 investor. Prominent investors backing the company include Beckman Coulter.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Clinical diagnostic products are manufactured for biomedical testing.
|
Locked | Locked | Locked |
Investor details for Cogenics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cogenics
Investment portfolio details for Cogenics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cogenics
Detailed financials for Cogenics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cogenics Comparisons
Peer comparison for Cogenics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cogenics
Detailed competitors of Cogenics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cogenics
Complete news archive for Cogenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cogenics
Gene synthesis, sequencing, and molecular biology services are offered by Cogenics in the biotechnology sector. Next-generation sequencing, Sanger sequencing, PCR, and related techniques are encompassed within these offerings. Plasmid preparation, oligo synthesis, and nucleic acid extraction are included among the core services. Preclinical and clinical support is provided through GLP-compliant testing and CLIA-certified variant confirmation. Research in gene therapy, cancer, and infectious diseases is facilitated by these capabilities.
Cogenics has 1 investor. Key investors include Beckman Coulter.